hemorrhagic disease of newborn
MONDO:0006784
A condition characterized as a coagulation disturbance in newborns due to vitamin K deficiency resulting in impaired production of coagulation factors II, VII, IX, and X, and proteins C and S by the liver.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Vitamin K deficiency bleeding
Vitamin K deficiency bleeding (VKDB) of the newborn, previously known as haemorrhagic disease of the newborn, is a rare form of bleeding disorder that affects newborns and young infants due to low stores of vitamin K at birth. It commonly presents with intracranial haemorrhage with the risk of brain damage or death. Newborn infants have low stores of vitamin K, and human breast milk has little Vitamin K. This combination can lead to vitamin K deficiency and later onset bleeding. Vitamin K deficiency leads to the risk of blood coagulation problems due to impaired production of clotting factors II, VII, IX, X, protein C, and protein S by the liver. More rarely, VKDB can be caused by maternal medications that cause vitamin K deficiency in the newborn. VKDB can be prevented by supplementing vitamin K, typically given shortly after birth by intramuscular injection. Most national health organisations recommend routine vitamin K supplementation after birth. Widespread use of this has made this a rare disease.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.